NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its first quarter revenues rose 21 percent year over year, thanks to momentum from the recent launch of its kidney transplant test Allosure.

For the three months ended March 31, the diagnostics company said revenues rose to $14.1 million from $11.6 million in Q1 2017, beating analysts' average estimate of $13.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.